Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg)

ConditionCovid19
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedialis Ltd.

About this trial

Coronavirus Disease 2019 (COVID-19) is a newly emerged disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic is having a large impact on the mental and physical health of patients, yet data on the quality of life of post-COVID-19 patients is lacking. There are currently no post-COVID-19 specific measures for quality of life, particularly none which include the views of post-COVID-19 patients themselves. This observational study will recruit participants to contribute their preferences to the creation of a post-COVID-19 specific patient-reported measure on post-COVID-19 quality of life. Participants will be split into three groups: those who were not hospitalised; those who were hospitalised but not in intensive care units; and those who were hospitalised and in intensive care units. The creation of this measure will form phase 1 of the study, with 30-60 participants (10-20 in each group above) recruited to complete online surveys to find out their preferences of areas of life to include in such a measure. This will involve 3 online surveys, 1) to ask which areas of life they feel are impacted and how; 2) to find consensus about the areas to be included; 3) to weight the relevance of these areas in relation to each other. In phase 2 recruitment will open to additional participants and all participants will be asked to complete the finalised post-COVID-19 quality of life measure once a month for 12 months, aiming for a minimum of 100 participants at this stage. All participants will also be asked to complete a demographic questionnaire to inform the analysis of the data.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

The participant has had either a confirmed COVID-19 test while infected or a confirmed COVID-19 antibody test post-infection

The participant is aged 18 years or older

The participant is capable of providing informed consent

The participant can read, write and converse in English

Disqualifiers

The participant does not have a confirmed COVID-19 test or antibody test

The participant is aged under 18 years

The participant is not capable of giving informed consent

The participant is unable to read, write and converse in English

Trial population

Participants will have a confirmed diagnosis of COVID-19 from either a test while infected or an antibody test post infection for Phase One. Participants in Phase Two will have either confirmed test/antibody test or clinical diagnosis of COVID-19

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • No intervention - quality of life measure

    Other intervention

    Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months

Treatment groups

100 Participants
are divided into 3 treatment groups
Group A: Non-hospitalised post-COVID-19 patients1 intervention
Group B: Hospitalised post-COVID-19 patients1 intervention
Group C: Intensive care post-COVID-19 patients1 intervention

Trial outcomes

Primary outcomes

1

Design of PAC19QoL Measure (Phase One)

The design and creation of a Post-COVID-19 Quality of Life Measure

Time frame
3 months
2

Completion of PAC19QoL Measure monthly for 12 months (Phase Two)

Participants in Phase Two will complete the newly designed Post-COVID-19 quality of life measure each month for 12 months

Time frame
12 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.